Propel Bio Management, LLC Phathom Pharmaceuticals, Inc. Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q1 2024
A detailed history of Propel Bio Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 869,927 shares of PHAT stock, worth $8.96 Million. This represents 5.38% of its overall portfolio holdings.
Number of Shares
869,927
Previous 443,047
96.35%
Holding current value
$8.96 Million
Previous $4.05 Billion
128.4%
% of portfolio
5.38%
Previous 3.35%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$104 Million5.64% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$76.9 Million20.79% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$36 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$32.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$28.3 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $404M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...